Evidence map›Paper›PMID 26617957›Full record

ArticleACS medicinal chemistry letters2015

Exploring Oxidovanadium(IV) Complexes as YopH Inhibitors: Mechanism of Action and Modeling Studies.

Priscila G A Martins, Mattia Mori, Louise D Chiaradia-Delatorre, Angela C O Menegatti, Alessandra Mascarello, Bruno Botta, Julio Benítez, Dinorah Gambino, Hernán Terenzi

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Priscila G A MartinsCentro de Biologia Molecular Estrutural-CEBIME, Universidade Federal de Santa Catarina , Campus Trindade, 88040-900 Florianópolis, Santa Catarina, Brasil.
Mattia MoriCenter for Life NanoScience@Sapienza, Istituto Italiano di Tecnologia , viale Regina Elena 291, 00161 Roma, Italy.
Louise D Chiaradia-DelatorreCentro de Biologia Molecular Estrutural-CEBIME, Universidade Federal de Santa Catarina , Campus Trindade, 88040-900 Florianópolis, Santa Catarina, Brasil.
Angela C O MenegattiCentro de Biologia Molecular Estrutural-CEBIME, Universidade Federal de Santa Catarina , Campus Trindade, 88040-900 Florianópolis, Santa Catarina, Brasil.
Alessandra MascarelloCentro de Biologia Molecular Estrutural-CEBIME, Universidade Federal de Santa Catarina , Campus Trindade, 88040-900 Florianópolis, Santa Catarina, Brasil ; Dipartimento di Chimica e Tecnologia del Farmaco, Sapienza, Università di Roma , Piazzale Aldo Moro 5, 00185 Roma, Italy.
Bruno BottaDipartimento di Chimica e Tecnologia del Farmaco, Sapienza, Università di Roma , Piazzale Aldo Moro 5, 00185 Roma, Italy.
Julio BenítezCátedra de Química Inorgánica, Facultad de Química, Universidad de la República , Gral. Flores 2124, 11800 Montevideo, Uruguay.
Dinorah GambinoCátedra de Química Inorgánica, Facultad de Química, Universidad de la República , Gral. Flores 2124, 11800 Montevideo, Uruguay.
Hernán TerenziCentro de Biologia Molecular Estrutural-CEBIME, Universidade Federal de Santa Catarina , Campus Trindade, 88040-900 Florianópolis, Santa Catarina, Brasil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

YopH tyrosine phosphatase, a virulence factor produced by pathogenic species of Yersinia, is an attractive drug target. In this work, three oxidovanadium(IV) complexes were assayed against recombinant YopH and showed strong inhibition of the enzyme in the nanomolar range. Molecular modeling indicated that their binding is reinforced by H-bond, cation-π, and π-π interactions conferring specificity toward YopH. These complexes are thus interesting lead molecules for phosphatase inhibitor drug discovery.

Indexed as

oxidovanadiumphosphatase inhibitionTyrosine phosphataseYersiniaYopH

Identifiers

PMID26617957
PMCPMC4641580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.